January 21, 2016Open Access

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Key Points

Key points are not available for this paper at this time.

Abstract

PSMA RLT with (177)Lu-PSMA is feasible, safe, and effective in end-stage progressive mCRPC with appropriate selection and follow-up of patients by (68)Ga-PSMA PET/CT through application of the concept of theranostics.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Richard P. Baum

Helios Dr. Horst Schmidt Kliniken Wiesbaden

Harshad Kulkarni

Indian Institute of Technology Mandi

Christiane Schuchardt

Zentralklinik Bad Berka

Journals

Journal of Nuclear Medicine

Actions

Institutions

Technical University of Munich

Zentralklinik Bad Berka

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study